ClinConnect ClinConnect Logo
Search / Trial NCT02787213

A Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor

Launched by SERA PROGNOSTICS, INC. · May 25, 2016

Trial Information

Current as of April 25, 2025

Completed

Keywords

Proteomics Pregnancy Biomarkers Preterm Birth

ClinConnect Summary

No description provided

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Subject is 18 years of age or older
  • Subject has singleton gestation
  • Subject is able to provide consent
  • Gestational age is confirmed by a documented crown rump length on an ultrasound performed at the study site within 6 0/7 weeks and 13 6/7 weeks gestation (first trimester)
  • Subject has no signs and/or symptoms of preterm labor and has intact membranes
  • Investigator believes subject is willing to comply with study visits and procedures
  • Investigator believes the subject's delivery data will be available within 15 business days from delivery, and neonatal data will be available for data collection purposes within 15 business days from discharge
  • Exclusion Criteria:
  • The subject has a planned cesarean section or induction of labor prior to 370/7 weeks of gestation
  • The subject has a planned cerclage placement for the current pregnancy
  • There is a known or suspected fetal anomaly or chromosomal abnormality
  • The subject has had a blood transfusion during the current pregnancy
  • The subject has known elevated bilirubin levels (hyperbilirubinemia)
  • * The subject has taken or plans to take any of the following medications during the current pregnancy:
  • Progesterone or progesterone-derivative medication after 13 6/7 weeks gestation
  • Enoxaparin, heparin, heparin sodium, low molecular weight heparin after first day of last menstrual period
  • The subject has participated in, or plans to participate in, an interventional treatment study during the current pregnancy
  • The current pregnancy was previously a multiple gestation that is now a single fetus due to reduction, vanishing twin, etc.

Trial Officials

Durlin E Hickok, MD

Study Chair

Sera Prognostics

About Sera Prognostics, Inc.

Sera Prognostics, Inc. is a leading biotechnology company dedicated to advancing women's health through innovative diagnostic solutions. With a focus on developing predictive tests for pregnancy-related complications, the company harnesses cutting-edge technology and extensive clinical research to improve maternal and neonatal outcomes. Sera Prognostics is committed to delivering actionable insights that empower healthcare providers and patients, ultimately enhancing the quality of care in obstetrics. By prioritizing scientific rigor and collaboration, the company aims to transform prenatal care and support healthier pregnancies worldwide.

Locations

Durham, North Carolina, United States

Orange, California, United States

Charleston, South Carolina, United States

Springfield, Massachusetts, United States

Chicago, Illinois, United States

Boston, Massachusetts, United States

Galveston, Texas, United States

Philadelphia, Pennsylvania, United States

Chapel Hill, North Carolina, United States

Galveston, Texas, United States

Indianapolis, Indiana, United States

Portland, Oregon, United States

Denver, Colorado, United States

New Orleans, Louisiana, United States

Aurora, Colorado, United States

Greenville, South Carolina, United States

Phoenix, Arizona, United States

San Diego, California, United States

Chattanooga, Tennessee, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials